Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies

Agnieszka Anna Rucki, Lei Zheng

Research output: Contribution to journalArticle

Abstract

Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United States and in the world. Late diagnosis, early metastasis and lack of effective therapy are among the reasons why only 6% of patients diagnosed with PDA survive past 5 years. Despite development of targeted therapy against other cancers, little progression has been made in the treatment of PDA. Therefore, there is an urgent need for the development of new treatments. However, in order to proceed with treatments, the complicated biology of PDA needs to be understood first. Interestingly, majority of the tumor volume is not made of malignant epithelial cells but of stroma. In recent years, it has become evident that there is an important interaction between the stromal compartment and the less prevalent malignant cells, leading to cancer progression. The stroma not only serves as a growth promoting source of signals but it is also a physical barrier to drug delivery. Understanding the tumor-stroma signaling leading to development of desmoplastic reaction and tumor progression can lead to the development of therapies to decrease stromal activity and improve drug delivery. In this review, we focus on how the current understanding of biology of the pancreatic tumor microenvironment can be translated into the development of targeted therapy.

Original languageEnglish (US)
Pages (from-to)2237-2246
Number of pages10
JournalWorld Journal of Gastroenterology
Volume20
Issue number9
DOIs
StatePublished - 2014

Fingerprint

Pancreatic Neoplasms
Adenocarcinoma
Neoplasms
Therapeutics
Architectural Accessibility
Tumor Microenvironment
Delayed Diagnosis
Tumor Burden
Pharmaceutical Preparations
Epithelial Cells
Neoplasm Metastasis
Growth

Keywords

  • Cancer associated fibroblast
  • Fibroblast activation protein
  • Hepatic growth factor
  • Pancreatic ductal adenocarcinoma
  • Pancreatic stellate cells
  • Sonic hedgehog
  • Stroma
  • Tumor microenvironment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Pancreatic cancer stroma : Understanding biology leads to new therapeutic strategies. / Rucki, Agnieszka Anna; Zheng, Lei.

In: World Journal of Gastroenterology, Vol. 20, No. 9, 2014, p. 2237-2246.

Research output: Contribution to journalArticle

@article{358defdc5ff7464b8d32b0e587b4f4f2,
title = "Pancreatic cancer stroma: Understanding biology leads to new therapeutic strategies",
abstract = "Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United States and in the world. Late diagnosis, early metastasis and lack of effective therapy are among the reasons why only 6{\%} of patients diagnosed with PDA survive past 5 years. Despite development of targeted therapy against other cancers, little progression has been made in the treatment of PDA. Therefore, there is an urgent need for the development of new treatments. However, in order to proceed with treatments, the complicated biology of PDA needs to be understood first. Interestingly, majority of the tumor volume is not made of malignant epithelial cells but of stroma. In recent years, it has become evident that there is an important interaction between the stromal compartment and the less prevalent malignant cells, leading to cancer progression. The stroma not only serves as a growth promoting source of signals but it is also a physical barrier to drug delivery. Understanding the tumor-stroma signaling leading to development of desmoplastic reaction and tumor progression can lead to the development of therapies to decrease stromal activity and improve drug delivery. In this review, we focus on how the current understanding of biology of the pancreatic tumor microenvironment can be translated into the development of targeted therapy.",
keywords = "Cancer associated fibroblast, Fibroblast activation protein, Hepatic growth factor, Pancreatic ductal adenocarcinoma, Pancreatic stellate cells, Sonic hedgehog, Stroma, Tumor microenvironment",
author = "Rucki, {Agnieszka Anna} and Lei Zheng",
year = "2014",
doi = "10.3748/wjg.v20.i9.2237",
language = "English (US)",
volume = "20",
pages = "2237--2246",
journal = "World Journal of Gastroenterology",
issn = "1007-9327",
publisher = "WJG Press",
number = "9",

}

TY - JOUR

T1 - Pancreatic cancer stroma

T2 - Understanding biology leads to new therapeutic strategies

AU - Rucki, Agnieszka Anna

AU - Zheng, Lei

PY - 2014

Y1 - 2014

N2 - Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United States and in the world. Late diagnosis, early metastasis and lack of effective therapy are among the reasons why only 6% of patients diagnosed with PDA survive past 5 years. Despite development of targeted therapy against other cancers, little progression has been made in the treatment of PDA. Therefore, there is an urgent need for the development of new treatments. However, in order to proceed with treatments, the complicated biology of PDA needs to be understood first. Interestingly, majority of the tumor volume is not made of malignant epithelial cells but of stroma. In recent years, it has become evident that there is an important interaction between the stromal compartment and the less prevalent malignant cells, leading to cancer progression. The stroma not only serves as a growth promoting source of signals but it is also a physical barrier to drug delivery. Understanding the tumor-stroma signaling leading to development of desmoplastic reaction and tumor progression can lead to the development of therapies to decrease stromal activity and improve drug delivery. In this review, we focus on how the current understanding of biology of the pancreatic tumor microenvironment can be translated into the development of targeted therapy.

AB - Pancreatic ductal adenocarcinoma (PDA) is among the deadliest cancers in the United States and in the world. Late diagnosis, early metastasis and lack of effective therapy are among the reasons why only 6% of patients diagnosed with PDA survive past 5 years. Despite development of targeted therapy against other cancers, little progression has been made in the treatment of PDA. Therefore, there is an urgent need for the development of new treatments. However, in order to proceed with treatments, the complicated biology of PDA needs to be understood first. Interestingly, majority of the tumor volume is not made of malignant epithelial cells but of stroma. In recent years, it has become evident that there is an important interaction between the stromal compartment and the less prevalent malignant cells, leading to cancer progression. The stroma not only serves as a growth promoting source of signals but it is also a physical barrier to drug delivery. Understanding the tumor-stroma signaling leading to development of desmoplastic reaction and tumor progression can lead to the development of therapies to decrease stromal activity and improve drug delivery. In this review, we focus on how the current understanding of biology of the pancreatic tumor microenvironment can be translated into the development of targeted therapy.

KW - Cancer associated fibroblast

KW - Fibroblast activation protein

KW - Hepatic growth factor

KW - Pancreatic ductal adenocarcinoma

KW - Pancreatic stellate cells

KW - Sonic hedgehog

KW - Stroma

KW - Tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=84895891540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895891540&partnerID=8YFLogxK

U2 - 10.3748/wjg.v20.i9.2237

DO - 10.3748/wjg.v20.i9.2237

M3 - Article

C2 - 24605023

AN - SCOPUS:84895891540

VL - 20

SP - 2237

EP - 2246

JO - World Journal of Gastroenterology

JF - World Journal of Gastroenterology

SN - 1007-9327

IS - 9

ER -